AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ AbbVie reported Q3 2026 net revenue of US$17.4 billion, marking a 10.3% year-over-year increase compared to the prior period.

πŸ’° Basic earnings per share surged to US$2.38 from US$0.10 in the previous year, reflecting a massive improvement in profitability.

🧬 Immunology and neuroscience segments drove operational revenue growth of 10.5%, supported by strong performance from Skyrizi, Rinvoq, and Vraylar.

πŸ“‰ Oncology revenue faced headwinds with Imbruvica sales declining 29.4% operationally due to pricing rules and competitive share pressure.

πŸš€ Management raised full-year adjusted earnings guidance following the release of strong third-quarter financial results.

πŸ’Ό The company successfully closed the Apogee acquisition, adding to its portfolio of innovative therapies.

πŸ”¬ Progress was highlighted on oncology pipeline candidates etentamig and epcoritamab, indicating depth in the cancer franchise.

πŸ’΅ Cash flow analysis suggests the stock could be undervalued by approximately 28% based on current metrics.

πŸ“Š The stock price climbed roughly 21% over the past three months prior to the earnings release.

βš–οΈ Analysts note that while oncology pressure exists, it has not yet caused broad erosion across the entire segment.

Bullish Signals
  • AbbVie reported strong Q3 2026 results with net revenue of US$17.4 billion and basic EPS of US$2.38, significantly beating market expectations.
  • The company achieved a 10.5% operational revenue growth in its immunology and neuroscience segments, driven by leaders like Skyrizi and Rinvoq.
  • Management successfully raised full-year adjusted earnings guidance following the release of robust third-quarter financial performance.
  • The stock price rose an additional 3.1% to US$294.83 immediately after the earnings announcement, reflecting positive investor sentiment.
  • Cash flow analysis indicates the company is potentially undervalued by approximately 28% when looking at its own cash flows.
  • The company closed the Apogee acquisition and highlighted significant progress on oncology pipeline candidates etentamig and epcoritamab.
Risk Factors
  • Imbruvica sales fell 29.4% operationally in Q3 2026 due to pricing rules and competitive share pressure, raising concerns about the oncology franchise.
  • There is a risk that further pressure on older oncology products could offset growth from newer assets and limit overall segment contribution.
  • Investors remain uneasy about paying up for a stock that had already risen roughly 21% over the past three months prior to earnings.
Full Analysis
AbbVie (ABBV) reported strong third-quarter results for Q3 2026, driving its stock price up approximately 3.1% to US$294.83 following the release. The company delivered net revenue of US$17.4 billion and basic earnings per share of US$2.38, representing significant growth compared to the prior year period. The financial performance was bolstered by a substantial increase in adjusted EPS and operational revenue growth of 10.5%, primarily driven by its immunology and neuroscience portfolios. Key assets such as Skyrizi, Rinvoq, and Vraylar contributed to this expansion, validating the company's strategy of replacing declining blockbuster revenues with new pipeline successes. However, investors remain cautious regarding potential headwinds in the oncology segment, where Imbruvica sales fell 29.4% operationally due to pricing pressures and competition. While management maintains guidance for total oncology revenue around US$6.6 billion for the full year, there is a noted risk that further erosion in this segment could offset gains from newer assets. Despite these concerns, analysts view the stock as potentially undervalued at roughly 28% based on cash flow metrics. The company successfully closed the Apogee acquisition and highlighted progress on oncology candidates etentamig and epcoritamab, suggesting a robust pipeline capable of sustaining long-term growth.